Cancer

Mouse studies suggest MAPKAPK2 inhibitors could help treat colorectal cancer. In a mouse model of colorectal cancer, systemic MAPKAPK2 knockout decreased tumor number, tumor volume and intestinal polyps and increased survival compared with normal MAPKAP2 expression. Also in the model, two tool compound MAPKAPK2 inhibitors decreased tumor number and volume compared with vehicle. In a mouse model of colitis-associated colorectal cancer, systemic MAPKAPK2 knockout decreased tumor volume compared with normal MAPKAP2 expression. Next steps include developing and testing MAPKAPK2 inhibitors for colorectal cancer.

Moerae Matrix Inc. and Teva Pharmaceutical Industries Ltd. have the MAPKAPK2 inhibitor MMI-0100 in Phase I testing to treat pulmonary fibrosis and inflammation...